Conference Summaries: Day Four<BR> Wednesday, February 2, 2000

The Body Covers: The 7th Conference on Retroviruses and Opportunistic Infections

Conference Summaries: Day Four
Wednesday, February 2, 2000

Session 78 -- State of the Art Lecture: Critical Issues in Antiretroviral Therapy
Coverage by Seattle Treatment Education Project
- L7: Critical Issues in Antiretroviral Therapy
Session 82 -- Pediatric/Maternal-Fetal Treatment Issues
Coverage by Mark Holodniy, M.D.
- Slide 661: Nelfinavir (NFV) Pharmacokinetics in Combination with Ritonavir (RTV) in Infants and Children with Advanced HIV Disease
Session 83 -- Antiviral Therapy: New Drugs
Coverage by Paul Sax, M.D.
- Slide 666: Alkylglycerol Foscarnet Analogs are Active in vitro at Submicromolar Concentrations against a Panel of Drug-Resistant Strains of HIV-1
- Slide 667: Potency, Breadth, and Durability of the Antiviral Activity of PRO 140, a Novel Inhibitor of CCR5-Mediated HIV-1 Entry
Coverage by Seattle Treatment Education Project
Session 84 -- Issues in HIV-1 Infection in Women
Coverage by Melanie Thompson, M.D.
- Poster 677: Weekly Treatment for Prophylaxis of Candida Vaginitis
- Poster 682: Causes and Rates of Death among HIV-Infected Women 1993-1998: The Contribution of Illicit Drug Use and Suboptimal HAART Use
Session 88 -- Maternal/Fetal and Pediatric Pharmacokinetics of Antiretroviral Therapy
Coverage by Mark Holodniy, M.D.
- Poster 715: PACTG 353 A Phase I Study of Safety, Pharmacokinetics, and Antiviral Activity of Combination Nelfinavir (NFV), ZDV, and 3TC in HIV-Infected Pregnant Women and Their Infants
Session 89 -- Resistance to Antiretroviral Drugs
Coverage by Paul Sax, M.D.
- Poster 726: Cross-Resistance to Amprenavir in PI-Treated Patients
- Poster 731: Baseline Genotype and Phenotype Do Not Predict Response to ABT-378/Ritonavir in PI-Experienced Patients at 24 and 48 Weeks
Coverage by Doug Ward, M.D.
- Poster 740: Common, Rare, and New HIV-1 Resistance Profiles Observed in Routine Clinical Practice: A Survey of over 5,000 Isolates and the Characterization of a Novel 3TC Resistance Mutational Profile Lacking 184V
- Poster 750: Comparison of Viral Resistance Emerging over 48 Weeks of Therapy with IDV/COM vs. ABC/COM
Coverage by Rick Stryker, M.D., M.P.H.
- Poster 751: Genotypic and Phenotypic Analysis of HIV-1 from Patients Receiving Combination Therapy Containing Two Nucleoside Reverse Transcriptase Inhibitors (NRTI), a Protease Inhibitor, and Emvirine (EMV, Coactinon)
- Poster 752: Genotypic Characterization of Resistance in Patients Failing an EFV/ IDV/ NRTI Regimen (Study DMP266-020)
Session 93 -- Genotypic and Phenotypic Characterization of HIV for Therapeutic Decision-Making
Coverage by Mark Holodniy, M.D.
- Poster 788: Potential Clinical Impact of Small Differences between Virco Antivirogram and ViroLogic PhenoSense Assays for Abacavir in 3TC Experienced Patients
Late Breaker Session 2 -- Documentation of HIV-1 Superinfection and Acceleration of Disease Progression
Coverage by Seattle Treatment Education Project
- LB2: Documentation of HIV-1 Superinfection and Acceleration of Disease Progression
Late Breaker Session 5 -- It Is Safe to Discontinue Secondary Prophylaxis for PCP in HIV-Infected Patients Treated with HAART
Coverage by Seattle Treatment Education Project
- LB5: It Is Safe to Discontinue Secondary Prophylaxis for PCP in HIV-Infected Patients Treated with HAART: Results from Eight Prospective European Cohorts
Late Breaker Session 6 -- Pharmacokinetic Interactions between Protease Inhibitors and Selected HMG-CoA Reductase Inhibitors
Coverage by Seattle Treatment Education Project
- LB6: Pharmacokinetic Interactions between Protease Inhibitors and Selected HMG-CoA Reductase Inhibitors
Late Breaker Session 7 -- A Randomized, Placebo-Controlled Trial of Saquinavir, Indinavir or Nelfinavir in Combination with Amprenavir, Abacavir, Efavirenz & Adefovir in Patients with PI Failure
Coverage by Seattle Treatment Education Project
- LB7: A Randomized, Placebo-Controlled Trial of Saquinavir (SQV)sgc, Indinavir (IDV) or Nelfinavir (NFV) in Combination with Amprenavir (APV), Abacavir (ABC), Efavirenz (EFZ) & Adefovir (ADV) in Patients (Pts) with Protease Inhibitor (PI) Failure
Late Breaker Session 10 -- Virologic and Immunologic Evaluation of Structured Treatment Interruptions in Patients Experiencing Long-term Virologic Failure
Coverage by Seattle Treatment Education Project
- LB10: Virologic and Immunologic Evaluation of Structured Treatment Interruptions (STI) in Patients Experiencing Long-term Virologic Failure
Late Breaker Session 11 -- Structured Cyclic Antiretroviral Therapy Interruption in Chronic Infection May Induce Immune Responses Against HIV-1 Antigens Associated with Spontaneous Drop in Viral Load
Coverage by Seattle Treatment Education Project
- LB11: Structured Cyclic Antiretroviral Therapy Interruption (STI) in Chronic Infection May Induce Immune Responses Against HIV-1 Antigens Associated with Spontaneous Drop in Viral Load

STEP Conference Coverage

Hear the Lectures from The 7th Conference on Retroviruses and Opportunistic Infections

Hear the Symposia from The 7th Conference on Retroviruses and Opportunistic Infections

Browse or search the abstracts

Return to The Body's coverage of
The 7th Conference on Retroviruses and Opportunistic Infections.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.